Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease

Chinese Medical Journal

Volumn 125, Issue 6, 2012, Pages 1147-1152

  Ni, Jie ^a   Huang, Hai Quan ^a   Lü, Lin Li ^a   Zheng, Min ^a   Liu, Bi Cheng ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Angiotensin receptor antagonists; Cytokines; Kidney diseases; Protein array analysis; Urine

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; MALE; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN MICROARRAY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CHRONIC DISEASE; CREATININE; CROSS-OVER STUDIES; CYTOKINES; HUMANS; KIDNEY DISEASES; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 84862268833     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.06.032     Document Type: Article

References (25)

1. Woo KT, Wong KS, Chan CM. Clinical trials of the past decade in the management of chronic kidney disease. Rev Recent Clin Trials 2009; 4: 159-162.
2. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
3. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
4. Liu BC, Zhang JD, Zhang XL, Wu GQ, Li MX. Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells. Clin Chim Acta 2006; 373: 144-150.
5. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009; 54: 877-884.
6. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311-1316.
7. Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67-73.
8. Vieitez P, Gomez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9: 96-102.
9. Kilis-Pstrusinska K. Genetic factors in the development and progression of chronic kidney disease. Postepy Hig Med Dosw (Online) 2010; 64: 50-57.
10. Liu BC, Zhang L, Lv LL, Wang YL, Liu DG, Zhang XL. Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 2006; 26: 483-490.
11. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
12. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
13. Liu BC, Lü LL. Novel biomarkers for progression of chronic kidney disease. Chin Med J 2010; 123: 1789-1792.
14. Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, et al. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology (Carlton) 2009; 14: 581-587.
15. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med 2008; 120: 33-42.
16. Li MX, Liu BC. Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis. Chin Med J 2007; 120: 1925-1930.
17. Zoja C, Garcia PB, Remuzzi G The role of chemokines in progressive renal disease. Front Biosci 2009; 14: 1815-1822.
18. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401-415.
19. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; 62: s12-s22.
20. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: 206-212.
21. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155-RA162.
22. Weidanz JA, Jacobson LM, Muehrer RJ, Djamali A, Hullett DA, Sprague J, et al. ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro. Kidney Int 2005; 67: 2134-2142.
23. Tone A, Shikata K, Ogawa D, Sasaki S, Nagase R, Sasaki M, et al. Changes of gene expression profiles in macrophages stimulated by angiotensin II: angiotensin II induces MCP-2 through AT1-receptor. J Renin Angiotensin Aldosterone Syst 2007; 8: 45-50.
24. Jones B, Kenward M. Design and analysis of cross-over trials. London: Chapman and Hall; 2003: 1.
25. Kacena KA, Quinn SB, Hartman SC, Quinn TC, Gaydos CA. Pooling of urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol 1998; 36: 3624-3628.